RARX: Ra Pharmaceuticals, Inc. Stock

Valuation
Market Cap ($M) 585.03
Enterprise Value ($M) 339.79
Book Value ($M) 80.46
Book Value / Share 2.48
Price / Book 6.16
NCAV ($M) 73.40
NCAV / Share 2.27
Price / NCAV 5.73

Profitability (mra)
Return on Invested Capital (ROIC) -0.79
Return on Assets (ROA) -0.43
Return on Equity (ROE) -0.46

Liquidity (mrq)
Quick Ratio n/a
Current Ratio 10.29

Balance Sheet (mrq) ($M)
Current Assets 83.56
Assets 90.62
Liabilities 10.16
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -55.03
Net Income -54.44
Earnings Per Share Basic And Diluted -2.41

Cash Flow Statement (mra) ($M)
Cash From Operations -46.78
Cash from Investing -1.41
Cash from Financing -1.41

Source:
Fintel.io

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
2018-03-02 13D/A Novo A/S 4.90 -24.61
2018-02-27 13D/A New Enterprise Associates 13 Lp 17.70 57.31
2018-02-16 13D/A RA Capital Management, LLC 12.70 184.94
2018-02-14 13G Novartis Ag 7.20
2018-02-08 13G/A Wellington Management Group LLP 12.23 20.29
2018-02-02 13G/A Novartis Bioventures Ltd 7.14 -36.52

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

Source:
Fintel.io

Date Insider Trades Code Shares Value

Source:
Fintel.io

File Date Form SEC Filings
2018-11-07 10-Q RARX / Ra Pharmaceuticals, Inc. 10-Q (Quarterly Report)
2018-08-08 10-Q RARX / Ra Pharmaceuticals, Inc. 10-Q (Quarterly Report)
2018-05-09 10-Q RARX / Ra Pharmaceuticals, Inc. 10-Q (Quarterly Report)
2018-03-14 10-K RARX / Ra Pharmaceuticals, Inc. 10-K (Annual Report)

Source:
Fintel.io


Financial data and stock pages provided for FREE by
Fintel.io